Respiratory syncytial virus season has officially begun in Romania, bringing severe infection risks and thousands of annual hospitalizations for infants, as announced by the Societatea Română de Pneumologie.
The virus circulates widely, with nearly all children encountering the pathogen by their second birthday. While older children experience mild symptoms, infants face severe pulmonary strain.
“Sugarii de vârstă mică sunt extrem de vulnerabili, întrucât au un nivel redus de anticorpi împotriva VSR, iar diametrul căilor aeriene este mult mai mic față de cel al copiilor mai mari,” said Oana Falup-Pecurariu, medic primar pediatru.
As the viral pathology progresses, it frequently triggers bronchiolitis, characterized by tachypnea, chest retractions, and wheezing.
Respiratory distress escalates rapidly, typically peaking between the third and fifth day of illness. Parents must monitor for severe lethargy, cyanosis around the lips, and the inability to feed properly.
“Dificultățile de respirație sunt cele care îi alarmează pe părinți: copilul respiră greu sau foarte repede și i se văd coastele când respiră,” Falup-Pecurariu said.
In Plain English: The Clinical Takeaway
- Narrow Airways: Infants possess exceptionally small bronchial diameters, meaning minimal inflammation causes significant air-flow obstruction.
- Immature Immunity: Neonates lack sufficient endogenous antibodies, leaving them defenceless against aggressive viral replication in the lower respiratory tract.
- Rapid Deterioration: Symptoms intensify swiftly between days three and five, demanding constant observation by caregivers.
Premature infants, newborns with cardiovascular, pulmonary or immune system issues, and immunocompromised children face the highest risk of developing severe forms of bronchiolitis.
Transmission occurs efficiently via respiratory secretions, direct contact, or contaminated environmental surfaces. School-aged siblings frequently contract the virus in classrooms and introduce it to vulnerable infants at home.
“Transmiterea se face foarte ușor, prin secreții respiratorii, contact direct, mâini sau suprafețe contaminate,” said Falup-Pecurariu.
| Patient Risk Category | Primary Clinical Vulnerability | Recommended Prevention Strategy |
|---|---|---|
| Preterm Infants | Underdeveloped lung architecture and low baseline antibodies | Long-acting monoclonal antibodies (nirsevimab, clesrovimab) |
| Congenital Heart/Lung Disease | Compromised cardiopulmonary reserve during viral stress | Specialized prophylaxis per pediatric specialist |
| Full-Term Healthy Infants | Narrow airway geometry and immature immune response | Maternal vaccination during pregnancy or infant monoclonal antibodies |
Similarly, corticosteroids are not recommended for routine management of typical bronchiolitis.
Caregivers must seek immediate emergency medical evaluation if the infant exhibits severe intercostal retractions, rapid breathing, cyanosis, or complete refusal to feed. Medical interventions focus on supportive care, including nasal suctioning, adequate hydration, and supplemental oxygen administration when indicated.
“Tratamentul bronșiolitei este în principal unul de tip suportiv: menținerea nasului curat, hidratarea și, dacă este necesar, administrarea de oxigen,” explained Falup-Pecurariu.
Pregnant individuals can receive maternal vaccination, transferring antibodies produced by the mother to the child to protect the newborn during the first months of life.
For infants whose mothers were not vaccinated during gestation, long-acting monoclonal antibodies such as nirsevimab and clesrovimab offer direct protection. These preventative measures are available for eligible infants according to applicable recommendations.
“Există vaccinare doar pentru mame, prin care anticorpii produși de mamă sunt transferați copilului și îl vor proteja în primele luni de viață,” said Falup-Pecurariu.
- Societatea Română de Pneumologie anunță că a început sezonul bronșiolitei și al infecțiilor respiratorii severe provocate de Virusul Sincițial Respirator.
